Prognostic factors in primary cutaneous melanoma

Surgical Clinics of North America

Volumn 83, Issue 1, 2003, Pages 61-75

  Zettersten, Elizabeth ^a   Shaikh, Ladan ^a   Ramirez, Raymond ^a   Kashani Sabet, Mohammed ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; ANGIOGENESIS; CANCER INVASION; CANCER LOCALIZATION; CANCER SIZE; HUMAN; MALIGNANT LENTIGO; MELANOMA; MITOSIS RATE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEX DIFFERENCE; SKIN ULCER; SUPERFICIAL CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VASCULARIZATION;

DIAGNOSIS, DIFFERENTIAL; HUMANS; HUTCHINSON'S MELANOTIC FRECKLE; MELANOMA; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RISK FACTORS; SKIN NEOPLASMS;

EID: 0037302083     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6109(02)00094-4     Document Type: Review

References (95)

1. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19(16):3635-48.
2. Fleming ID, Cooper JS, Henson DE, et al. Malignant melanoma of the skin. In: Fleming ID, Cooper JS, Henson DE, et al, editors. American-Joint Committee on Staging manual. 5th edition. Philadelphia: Lippincott-Raven; 1997. p. 163-7.
3. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17, 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19(16):3622-34.
4. Austin PF, Cruse CW, Lyman G, et al. Age as a prognostic factor in the malignant melanoma population. Ann Surg Onc 1994;1(6):487-94.
5. Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224(3):255-63.
6. Balch CM, Soong SJ, Shaw HM, et al. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Balch CM, Houghton AN, Milton GW, et al, editors. Cutaneous melanoma. 2nd edition. Philadelphia: JB Lippincott; 1992. p. 165-87.
7. Masback A, Olsson H, Westerdahl J, et al. Prognostic factors in invasive cutaneous malignant melanoma: a population-based study and review. Melanoma Res 2001;11:435-45.
8. Schuchter L, Schultz DJ, Synnestvedt M, et al. A prognostic model for predicting 10-year survival in patients with primary melanoma. The pigmented lesion group. Ann Intern Med 1996;125(5):369-75.
9. Slingluff CL Jr, Vollmer RT, Reintgen DS, et al. Lethal "thin" malignant melanoma. Ann Surg 1988;208(2):150-61.
10. Clark WH, Elder DE, Guerry D 4th, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81(24):1893-904.
11. Garbe C, Buttner P, Bertz J, et al. Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5,093 patients. Cancer 1995;75:2484-91.
12. Shaw HM, McGovern VJ, Milton GW, et al. Malignant melanoma: influence of site of lesion and age of patients in the female superiority in survival. Cancer 1980;46(12):2731-5.
13. Soong SJ, Shaw HM, Balch CM, et al. Predicting survival and recurrence in localized melanoma: a multivariate approach. World J Surg 1992;16:191-5.
14. Thorn M, Ponten F, Bergstrom R, et al. Clinical and histopathologic predictors of survival in patients with malignant melanoma: a population-based study in Sweden. J Natl Cancer Inst 1994;86(10):761-9.
15. Unger JM, Flaherty LE, Liu PY, et al. Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials. Cancer 2001;91:1148-55.
16. Vossaert KA, Silverman MK, Kopf AW, et al. Influence of gender on survival in patients with stage I malignant melanoma. J Am Acad Dermatol 1992;26:429-40.
17. Balch CM. Cutaneous melanoma: prognosis and treatment worldwide. Semin Surg Oncol 1992;8:400-14.
18. Garbe C, Buttner P, Bertz J, et al. Primary cutaneous melanoma. Prognostic classification of anatomic location. Cancer 1995;75:2492-8.
19. Urist MM, Balch CM, Soong SJ, et al. Head and neck melanoma in 534 clinical stage I patients. A prognostic factors analysis and results of surgical treatment. Ann Surg 1984;200(6):769-75.
20. Day CL Jr, Sober AJ, Kopf AW, et al. A prognostic model for clinical stage I melanoma of the lower extremity. Surgery 1981;89(5):599-603.
21. Day CL Jr, Sober AJ, Kopf AW, et al. A prognostic model for clinical stage I melanoma of the upper extremity. The importance of anatomical subsites in predicting recurrent disease. Ann Surg 1981;193:436-40.
22. Wells KE, Reintgen DS, Cruse CW. The current management and prognosis of acral lentiginous melanoma. Am Plast Surg 1992;28(1):100-3.
23. Urist MM, Balch CM, Soong SJ, et al. The influence of surgical margins and prognostic factors predicting the risk of local recurrence in 3445 patients with primary cutaneous melanoma. Cancer 1985;55(6):1398-402.
24. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970;172(5):902-8.
25. Buttner P, Garbe C, Bertz J, et al. Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification. Cancer 1995;75(10):2499-506.
26. Buzaid AC, Ross MI, Balch CM, et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 1997;15(3):1039-51.
27. Balch CM, Soong SJ, Milton GW, et al. A comparison of prognostic factors and surgical results in 1786 patients with localized (stage 1) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg 1982;196:677-84.
28. Balch CM, Murad TM, Soong SJ, et al. A multifactorial analysis of melanoma. Prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg 1978;188:732-42.
29. Barnhill RL, Fine J, Roush GC, et al. Predicting five-year outcome from cutaneous melanoma in a population-based study. Cancer 1996;78(3):427-32.
30. Breslow A. Tumor thickness, level of invasion and node dissection in stage I cutaneous melanoma. Ann Surg 1975;182:572.
31. Kashani-Sabet M, Sagebiel RW, Ferreira CM, et al. Vascular involvement in the prognosis of primary cutaneous melanoma. Arch Dermatol 2001;137(9):1169-73.
32. Owen SA, Sanders LL, Edwards LJ, et al, Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV. Cancer 2001;91(5):983-91.
33. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II patients. J Clin Oncol 1999;17(3):976-83.
34. Cooper PH, Wanebo HJ, Hagar RW. Regression in thin malignant melanoma. Microscopic diagnosis and prognostic importance. Arch Dermatol 1985;121(9):1127-31.
35. Ronan SG, Eng AM, Briele HA, et al. Thin malignant melanomas with regression and metastases. Arch Dermatol 1987;123:1326-30.
36. Salman S, Rogers G. Prognostic factors in thin cutaneous melanoma. J Dermatol Surg Oncol 1990;16:413-8.
37. Trau H, Rigel DS, Harris MN, et al. Metastases of thin melanomas. Cancer 1983;51:553-6.
38. Vilmer C, Bailly C, Le Doussal V, et al. Thin melanomas with unusual aggressive behavior: a report on nine cases. Melanoma Group of French Federation of Cancer Centers. J Am Acad Dermatol 1996;34(3):439-44.
39. Elder DE, Guerry D 4th, Epstein MN, et al. Invasive malignant melanoma lacking competence for metastasis. Am J Dermatopathol 1984;6(Suppl):55-61.
40. Zettersten E, Sagebiel RW, Miller JR 3rd, et al. Prognostic factors in patients with thick cutaneous melanoma (>4 mm). Cancer 2002;94(4):1049-56.
41. Gershenwald JE, Mansfield PF, Lee JE, et al. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (>4 mm) primary melanoma. Ann Surg Oncol 2000;7:160-5.
42. Clark WH Jr, From L, Bernardino EA. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969;29(3):705-27.
43. Kelly JW, Sagebiel RW, Blois MS. Regression in malignant melanoma. A histological feature without independent prognostic significance. Cancer 1985;56(9):2287-91.
44. Balch CM, Wilkerson JA, Murad TM, et al. The prognostic significance of ulceration on cutaneous melanoma. Cancer 1980;45(12):3012-7.
45. Cochran AJ, Elashoff D, Morton DL. Individualized prognosis for melanoma patients. Hum Pathol 2000;31(3):327-31.
46. Finley JW, Gibbs JF, Rodriguez LM, et al. Pathologic and clinical features influencing outcome of thin cutaneous melanoma: correlation with newly proposed staging system. Am Surg 2000;66(6):527-31.
47. McGovern VJ, Shaw HM, Milton GW, et al. Ulceration and prognosis in cutaneous malignant melanoma. Histopathology 1982;6(4):399-407.
48. Reintgen DS, Cox C, Slingluff CL, et al. Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann Plast Surg 1992;28:45-9.
49. Shaw HM, Balch CM, Soong SJ, et al. Prognostic histopathological factors in malignant melanoma. Pathology 1985;17(2):271-4.
50. Kashani-Sabet M, Sagebiel RW, Ferreira CM, et al. Tumor vascularity in the prognostic assessment of primary cutaneous melanoma. J Clin Oncol 2002;20(7):1826-31.
51. Cascinelli N, Zurrida S, Galimberti V, et al. Acral Lentiginous Melanoma. J Dermatol Surg Oncol 1994;20:817-22.
52. Koh HK, Michalik E, Sober AJ, et al. Lentigo maligna melanoma has no better prognosis than other types of melanoma. J Clin Oncol 1984;2:994-1001.
53. Ridgeway CA, Hieken TJ, Ronan SG, et al. Acral lentiginous melanoma. Arch Surg 1995;130(1):88-92.
54. Vollmer RT. Malignant Melanoma: a multivariate analysis of prognostic factors. Pathol Annu 1989;24:383.
55. MacKie RM. Malignant melanoma: clinical variants and prognostic indicators. Clin Exp Dermatol 2000;25(6):471-5.
56. Langely RGB, Fitzpatrick TB, Sober AJ. Clinical Characteristics. In: Balch CM, Houghton A Jr, Sober A, editors. Cutaneous melanoma. 3rd edition. St. Louis: Quality Medical Publishing; 1998. p. 81-101.
57. Schmid-Wendtner MH, Brunner B, Konz B, et al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 Patients. J Am Acad Dermatol 2000;43(3):477-82.
58. Tsang RW, Liu FF, Wells W, et al. Lentigo maligna of the head and neck. Results of treatment by radiotherapy. Arch Dermatol 1994;130(8):1008-12.
59. Fitzpatrick TB, Milton GW, Balch CM, et al. Clinical characteristics. In: Balch CM, Houghton A Jr, Milton GW, et al, editors. Cutaneous melanoma. 2nd edition. Philadelphia: JB Lippincott; 1992. p. 227-9.
60. Reintgen DS, Cruse CW, Wells KE, et al. Isolated limb perfusion for recurrent melanoma of the extremity. Ann Plast Surg 1992;28(1):50-4.
61. Quinn MJ, Crotty KA, Thompson JF, et al. Desmoplastic melanoma and desmoplastic neurotropic melanoma. Cancer 1998;83:1128-35.
62. Jaroszewski DE, Pockaj BA, DiCaudo DJ, et al. Clinical behavior of desmoplastic melanoma. Am J Surg 2001;182(6):590-5.
63. Carlson JA, Egbert BM. Desmoplastic neurotropic malignant melanoma. Pathol 1994;2(2):339-57.
64. Thelmo MC, Sagebiel RW, Treseler PA, et al. Evaluation of sentinel lymph node status in spindle cell melanomas. J Am Acad Dermatol 2001;44(3):451-5.
65. Barnhill RL, Fandrey K, Levy MA, et al. Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma. Lab Invest 1992;67:331-7.
66. Marcoval J, Moreno A, Graells J, et al. Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase. J Cutan Pathol 1997;24:212-8.
67. Ribatti D, Vacca A, Palma W, et al. Angiogenesis during tumor progression in human malignant melanoma. EXS 1992;61:415-20.
68. Fallowfield ME, Cook MG. The vascularity of primary cutaneous melanoma. J Pathol 1991;164(3):241-4.
69. Straume O, Salvesen HB, Akslen LA. Angiogenesis is prognostically important in vertical growth phase melanomas. Int J Oncol 1999;15(3):595-9.
70. Le Querrec A, Duval D, Tobelem G. Tumour angiogenesis. Balliere's Clinical Hematology 1993;6(3):711-30.
71. Schmoeckel C, Bockelbrink A, Bockelbrink H, et al. Low- and high-risk malignant melanoma - I. Evaluation of clinical and histological prognosticators in 585 cases. Eur J Cancer Clin Oncol 1983;19(2):227-35.
72. Straume O, Akslen LA. Independent prognostic importance of vascular invasion in nodular melanomas. Cancer 1996;78:1211-9.
73. Blessing K, McLaren KM, McLean, et al. Thick malignant melanomas (greater than 3 mm Breslow) and with good clinical outcome: a histological study and survival analysis. Histopathology 1991;18(2):143-8.
74. Spatz A, Shaw HM, Crotty KA, et al. Analysis of histopathological factors associated with survival of 10 years or more for patients with thick melanomas (>5 mm). Histopathology 1998;33(5):406-13.
75. Day CL Jr, Harrist TJ, Gorstein F, et al. Prognostic significance of "microscopic satellites" in the reticular dermis and subcutaneous fat. Ann Surg 1981;194(1):108-12.
76. Day C.L.Jr, Mihm MC Jr, Lew RA, et al. Prognostic models for patients with clinical stage I melanoma of intermediate thickness (1.51-3.99 mm). Ann Surg 1982;195(1):35-43.
77. Harrist TJ, Rigel DS, Day CL, et al. "Microscopic satellites" are more highly associated with regional lymph node metastases than is primary melanoma thickness. Cancer 1984; 53(10):2183-7.
78. Kelly JW, Sagebiel RW, Clyman S, et al. Thin level IV malignant melanoma. A subset in which level is the major prognostic indicator. Ann Surg 1985;202(1):98-103.
79. Leon P, Daly JM, Synnestvedt M, et al. The prognostic implications of microscopic satellites in patients with clinical stage I melanoma. Arch Surg 1991;126:1461-8.
80. Schmoeckel C, Braun-Falco O. Prognostic index in malignant melanoma. Arch Dermatol 1978;114:871.
81. Day CL Jr, Sober AJ, Kopf AW, et al. A prognostic model for clinical stage I melanoma of the trunk. Am J Surg 1981;142:247-51.
82. Elder DE, Guerry D4th, VanHorn M, et al. The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51-3.99 mm). Cancer 1985;56:413-8.
83. Massi D, Borgognoni L, Franchi A, et al. Thick cutaneous malignant melanoma: a reappraisal of prognostic factors. Melanoma Res 2000;10(2):153-64.
84. McCarthy WH, Shaw HM, McCarthy SW, et al. Cutaneous melanomas that defy conventional prognostic indicators. Semin Oncol 1996;23(6):709-13.
85. Shaw HM, McCarthy WH, McCarthy SW, et al. Thin malignant melanoma and recurrence potential. Arch Surg 1987;122:1147-50.
86. Sondergaard K, Schou G. Prognostic significance of the histological features of malignant melanoma. Histopathology 1979;3(5):385-93.
87. Clemente CG, Mihm MC Jr, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996;77(7):1303-10.
88. Day CL Jr, Lew RA, Mihm MC, et al. A multivariate analysis of prognostic factors for melanoma patients with lesions >3.65 mm in thickness. Ann Surg 1982;195(1):44-9.
89. Day CL Jr, Mihm MC Jr, Sober AJ, et al. Prognostic factors for melanoma patients with lesions 0.76-1.69 mm in thickness. Ann Surg 1982;195(1):30-4.
90. McGovern VJ, Shaw HM, Milton GW, et al. Prognostic significance of the histological features of malignant melanoma. Histopathology 1979;3(5):385-93.
91. Gromet MA, Epstein WL, Blois MS. The regressing thin malignant melanoma. Cancer 1978;42:2282-92.
92. Kelly JW, Sagebiel RW, Calderon W, et al. The frequency of local recurrence and microsatellites as a guide to re-excision margins for cutaneous malignant melanoma. Ann Surg 1984;200(6):759-63.
93. McGovern VJ, Shaw HM, Milton GW. Prognosis in patients with thin malignant melanoma: influence of regression. Histopathology 1983;7:673-80.
94. Paladagu RR, Yonemoto RH. Biologic behaviour of thin malignant melanoma with regressive changes. Arch Surg 1983;118:41-4.
95. Mraz-Gernhard S, Sagebiel RW, Kashani-Sabet M, et al. Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma. Arch Dermatol 1998;134(8):983-7.